CABG cardiac surgery
Conditions
Interventions
Pretreatment with metformin (500 mg three times a day for at least 3 days - max
7 days - ) or placebo until the day of surgery
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Acceptation for CABG - Informed consent - Age >= 18 years
Exclusion criteria
Exclusion criteria: - Diabetes mellitus - Renal dysfunction (MDRD 3 times upper limit of reference range) - Treatment with dipyridamole or xanthine derivatives - Recent myocardial infarction (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High-sensitive troponin-I levels measured before and 6,12 and 24 hours after CABG. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints will include the post-operative occurrence of arrhythmias, the need for inotropic support, time to detubation, and time to discharge from the intensive care unit. Moreover, renal injury and function will be secondary endpoints of the study. Renal ischemia-reperfusion will be assessed by measuring urinary excretion of the markers of tubular damage Kidney Injury Molecule (KIM)-1 and neutrophil gelatinase-associated lipocalin (NGAL), and renal function will be assessed by plasma and urine concentrations of creatinine. Finally, the right auricle will be harvested during surgery to determine whether metformin augments recovery of contractile function of isolated atrial trabeculae after ex vivo simulated ischemia-reperfusion (vide infra) and to determine the effect of metformin on the expression and activation of protein kinases involved in ischemia-reperfusion injury (Western blotting). | — |
Countries
Netherlands
Outcome results
None listed